Andressa S. Laino

895 total citations
20 papers, 582 citations indexed

About

Andressa S. Laino is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Andressa S. Laino has authored 20 papers receiving a total of 582 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 11 papers in Molecular Biology and 5 papers in Immunology. Recurrent topics in Andressa S. Laino's work include Cancer Immunotherapy and Biomarkers (9 papers), Histone Deacetylase Inhibitors Research (8 papers) and CAR-T cell therapy research (6 papers). Andressa S. Laino is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Histone Deacetylase Inhibitors Research (8 papers) and CAR-T cell therapy research (6 papers). Andressa S. Laino collaborates with scholars based in United States, United Kingdom and France. Andressa S. Laino's co-authors include David Woods, Jeffrey S. Weber, Melinda Vassallo, Megan Wind‐Rotolo, Xiaozhong Qian, Hao Tang, Brian C. Betts, Tatsuya Yoshida, Junya Ichikawa and F. Stephen Hodi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Andressa S. Laino

20 papers receiving 573 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andressa S. Laino United States	11	382	273	204	56	45	20	582
Houssein Abdul Sater United States	11	373 1.0×	298 1.1×	122 0.6×	81 1.4×	41 0.9×	33	513
Nancy P. Judd United States	7	275 0.7×	262 1.0×	183 0.9×	66 1.2×	64 1.4×	7	544
Karan Kohli United States	8	337 0.9×	395 1.4×	135 0.7×	57 1.0×	33 0.7×	10	607
Dylan T. Ammons United States	6	279 0.7×	294 1.1×	131 0.6×	67 1.2×	49 1.1×	16	477
Cyril Šálek Czechia	14	275 0.7×	311 1.1×	243 1.2×	41 0.7×	74 1.6×	47	728
Simona Partlová Czechia	7	302 0.8×	294 1.1×	106 0.5×	53 0.9×	52 1.2×	12	497
Remy Thomas Qatar	10	376 1.0×	364 1.3×	265 1.3×	63 1.1×	71 1.6×	14	652
Jonathan J. Hodgins Canada	5	530 1.4×	631 2.3×	150 0.7×	55 1.0×	55 1.2×	7	803
Sabrina Carpentier France	9	225 0.6×	372 1.4×	128 0.6×	69 1.2×	89 2.0×	11	573
Kelli A. Connolly United States	6	305 0.8×	312 1.1×	113 0.6×	56 1.0×	52 1.2×	13	479

Countries citing papers authored by Andressa S. Laino

Since Specialization

Citations

This map shows the geographic impact of Andressa S. Laino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andressa S. Laino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andressa S. Laino more than expected).

Fields of papers citing papers by Andressa S. Laino

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andressa S. Laino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andressa S. Laino. The network helps show where Andressa S. Laino may publish in the future.

Co-authorship network of co-authors of Andressa S. Laino

This figure shows the co-authorship network connecting the top 25 collaborators of Andressa S. Laino. A scholar is included among the top collaborators of Andressa S. Laino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andressa S. Laino. Andressa S. Laino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sullivan, Ryan J., Oladapo Yeku, Deanna Teoh, et al.. (2025). First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer. The Oncologist. 30(6). 2 indexed citations

Weber, Jeffrey S., Benjamin Levinson, Andressa S. Laino, Anna C. Pavlick, & David Woods. (2022). Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma. Melanoma Research. 32(5). 324–333. 15 indexed citations

Ichikawa, Junya, Tatsuya Yoshida, Ariel Isser, et al.. (2020). Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells. Clinical Cancer Research. 26(13). 3384–3396. 34 indexed citations

Laino, Andressa S., David Woods, Melinda Vassallo, et al.. (2020). Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. Journal for ImmunoTherapy of Cancer. 8(1). e000842–e000842. 166 indexed citations

Yoshida, Tatsuya, Junya Ichikawa, Andressa S. Laino, et al.. (2020). C reactive protein impairs adaptive immunity in immune cells of patients with melanoma. Journal for ImmunoTherapy of Cancer. 8(1). e000234–e000234. 65 indexed citations

Woods, David, Andressa S. Laino, Aidan Winters, et al.. (2020). Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes. JCI Insight. 5(11). 15 indexed citations

Jimeno, Antonio, Shilpa Gupta, Ryan J. Sullivan, et al.. (2020). Abstract CT032: A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies. Cancer Research. 80(16_Supplement). CT032–CT032. 36 indexed citations

Woods, David, Andressa S. Laino, Melinda Vassallo, & Jeffrey S. Weber. (2020). Abstract PO-007: The Class I/IV HDAC Inhibitor Mocetinostat Augments Anti-Tumor Immune Responses in Melanoma Patients. Cancer Research. 80(23_Supplement). PO–7. 2 indexed citations

Weber, Jeffrey S., Andressa S. Laino, Melinda Vassallo, et al.. (2020). Preclinical and clinical studies of a class I/IV HDAC inhibitor, mocetinostat, in melanoma.. Journal of Clinical Oncology. 38(15_suppl). 10052–10052. 7 indexed citations

10.

Patel, Manish R., Todd M. Bauer, Antonio Jimeno, et al.. (2020). A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab.. Journal of Clinical Oncology. 38(15_suppl). 3092–3092. 57 indexed citations

11.

Weber, Jeffrey S., Hao Tang, Megan Wind‐Rotolo, et al.. (2019). Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.. Journal of Clinical Oncology. 37(15_suppl). 100–100. 38 indexed citations

12.

Laino, Andressa S., Brian C. Betts, Anandharaman Veerapathran, et al.. (2019). HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics. Journal for ImmunoTherapy of Cancer. 7(1). 33–33. 66 indexed citations

13.

Chattopadhyay, Pratip K., Aidan Winters, Woodrow E. Lomas, Andressa S. Laino, & David Woods. (2019). High-Parameter Single-Cell Analysis. Annual Review of Analytical Chemistry. 12(1). 411–430. 19 indexed citations

14.

Woods, David, Rupal Ramakrishnan, Andressa S. Laino, et al.. (2018). Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma. Clinical Cancer Research. 24(24). 6236–6247. 50 indexed citations

15.

Weber, Jeffrey S., Rupal Ramakrishnan, Andressa S. Laino, Anders Berglund, & David Woods. (2017). Association of changes in T regulatory cells (Treg) during nivolumab treatment with melanoma outcome.. Journal of Clinical Oncology. 35(15_suppl). 3031–3031. 2 indexed citations

16.

Cheng, Fengdong, Andressa S. Laino, Hongwei Wang, et al.. (2016). In vitro and in vivo anti-melanoma activity of ricolinostat, a selective HDAC6 inhibitor with immunomodulatory properties.. Journal of Clinical Oncology. 34(15_suppl). e21075–e21075. 1 indexed citations

17.

Laino, Andressa S., David Woods, Amod A. Sarnaik, Jeffrey S. Weber, & Eduardo M. Sotomayor. (2016). Abstract A074: Selective Inhibition of HDAC6 augments T-cell central memory and enhances anti-tumor functions: Implications in TIL therapy. Cancer Immunology Research. 4(1_Supplement). A074–A074. 1 indexed citations

18.

Laino, Andressa S., David Woods, Amod A. Sarnaik, et al.. (2015). Abstract 1338: Novel implications of histone deacetylase 6 selective inhibition in melanoma T-cell immunotherapy. Cancer Research. 75(15_Supplement). 1338–1338. 1 indexed citations

19.

Laino, Andressa S., David Woods, Fengdong Cheng, Hongwei Wang, & Eduardo M. Sotomayor. (2013). Histone Deacetylase 6 (HDAC6) Influences T-Cell Activation and Survival: Implications For Cancer Immunotherapy. Blood. 122(21). 1050–1050. 1 indexed citations

20.

Vargas, José Eduardo, et al.. (2012). pLR: A lentiviral backbone series to stable transduction of bicistronic genes and exchange of promoters. Plasmid. 68(3). 179–185. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact